Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials

The ONE Study showed that infusing patients' own regulatory immune cells after a living-donor kidney transplant is safe, allows lower doses of standard anti-rejection drugs, and is linked to fewer infections without raising rejection in the first year.